Guilford To Receive $40 Mil. To Fund Parkinson's/ED Drug Development Via Investment Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly formed corporation of investors, Symphony Neuro Development Company, will provide the funds in exchange for five-year warrants to purchase Guilford stock and exclusive rights to the drug. Guilford has an option to reacquire the drug for $75 mil.-$120 mil. between April 2005 and March 2007.
You may also be interested in...
With Pharma Ready to Pare Portfolios, Project Financing Funds Make Their Pitches
Drug firms need to find good homes for hundreds of early-stage experimental compounds that ideally they could claw back once new developers demonstrate proof-of-concept. New project financing funds are clamoring for those assets, but first they must convince LPs to invest in unproven financing models, deal with pharma's accounting demands, and negotiate deals with asset-holders that will provide a decent return.
With Pharma Ready to Pare Portfolios, Project Financing Funds Make Their Pitches
Drug firms need to find good homes for hundreds of early-stage experimental compounds that ideally they could claw back once new developers demonstrate proof-of-concept. New project financing funds are clamoring for those assets, but first they must convince LPs to invest in unproven financing models, deal with pharma's accounting demands, and negotiate deals with asset-holders that will provide a decent return.
Symphony's Project Financing Model Adapts
As Wall Street fails to significantly reward companies with strong clinical news, the fall-out also affects the project financiers, like Symphony Capital -- an increasingly important alternative to traditional equity or alliance financing. On one hand, the hard times make Symphony's expensive-looking capital increasingly attractive to biotechs, including companies that once would have had plenty of other financing alternatives. On the other, Symphony's model is shifting more toward equity investing. It's still financing projects, but it's padding its upside with a lot more cheap stock.